statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 352.6% during the fourth quarter, according to its most...

China Universal Asset Management Co. Ltd. Raises Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of...

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

For the last three days, A.I.dvisor has detected that ZNTL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Zentalis Pharmaceuticals (ZNTL, $16.13) Aroon Indicator entered a Downtrend on April 01, 2024.

NEW YORK and SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This is a Bullish indicator signaling ZNTL's price could rise from here. Traders may explore going long the stock or buying call options...

Zentalis Pharmaceuticals (ZNTL, $15.73) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL  Get Free Report)s stock price dropped 4.5% during trading on Wednesday . The stock traded as low as $13.28 and last traded at $13.30...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 4.5%

This is a Bearish indicator signaling ZNTL's price could decline from here. Traders may explore shorting the stock or put options...

Zentalis Pharmaceuticals (ZNTL, $14.11) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL  Get Free Report)s share price rose 7.7% during trading on Tuesday . The company traded as high as $15.03 and last traded at $15.01...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Up 7.7%

This indicator may be signaling that ZNTL's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Zentalis Pharmaceuticals (ZNTL, $15.36) entered Downtrend as Momentum indicator drops below 0 level on Mar 13, 2024

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL  Get Free Report) traded up 7.7% on Tuesday . The stock traded as high as $15.03 and last traded at $15.01. 176,839 shares traded hands during...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading 7.7% Higher

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.

Volume	854,473.00
52-Wk High	$31.46
52-Wk Low	$9.56

ZNTL Zentalis Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals